Billiontoone Inc (BLLN)

$100.03 -8.91 (-8.18%)
Market Cap N/A
Revenue (ttm) 152.58M
Net Income (ttm) -41.57M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin -27.24%
Debt to Equity Ratio N/A
Volume 461,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a l...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: (650) 460-2551
Address:
1035 O’Brien Drive, Menlo Park, United States
Amb8675309
Amb8675309 May. 12 at 5:40 PM
$BLLN another prediction: once they settle out of court with ILMN, ILMN will want a licensing percentage of all the tests they’ve already done for whatever period it is they’re being sued for. So you’re most likely going to see an announcement of a one time payment to ILMN for those tests, PLUS they now they have to pay a percentage licensing fee going forward, on every test. This is in today’s environment where payors are paying less in general, reimbursement wise, on tests. So be careful of “spin” during earnings calls where they brag about testing volume- reality is if amount reimbursed per test is falling, plus now ILMN gets a percentage on each test… not a business to be in anymore…
1 · Reply
Amb8675309
Amb8675309 May. 12 at 5:31 PM
$BLLN they’ve been selling their test for years- IP owned by Illumina- they’ve got a deep hold on patents- probable end result- a licensing deal which will take a bite out of already decreasing margins due to payors decreasing reimbursement amounts. This will settle out of court. Look up all the companies that Illumina has already sued. CEO is hard headed to think this wasn’t coming once he went public and started to steal market share in the NIPT space…
0 · Reply
Amb8675309
Amb8675309 May. 12 at 5:18 PM
$BLLN look in my timeline for BLLN- I called it re lawsuits- thought NTRA would be the one- looks like Illumina- infringement on IP
1 · Reply
Pavie99
Pavie99 May. 12 at 4:14 PM
$BLLN cmon down to loading levels :) Shake n bake!!!! 🏎
0 · Reply
PhishTourFunds
PhishTourFunds May. 11 at 11:55 PM
$BLLN
0 · Reply
Shlobby
Shlobby May. 11 at 10:56 PM
$BLLN they will find this 50 to 100% higher
1 · Reply
SmashDipRoll
SmashDipRoll May. 11 at 7:48 PM
$BLLN
0 · Reply
Shlobby
Shlobby May. 11 at 7:47 PM
Theres a new $BILI in town @Doozio cc $BLLN
0 · Reply
Bounty_Hunter1
Bounty_Hunter1 May. 11 at 6:52 PM
$BLLN
0 · Reply
Reanimated666
Reanimated666 May. 11 at 3:54 PM
$BLLN couldn’t make sense of the numbers yet this thing keeps going up I guess it’s good 👍
1 · Reply
Latest News on BLLN
BillionToOne price target raised to $120 from $100 at Guggenheim

2026-05-13T11:22:07.000Z - 3 hours ago

BillionToOne price target raised to $120 from $100 at Guggenheim

BillionToOne price target raised to $125 from $120 at JPMorgan

2026-05-07T15:38:45.000Z - 5 days ago

BillionToOne price target raised to $125 from $120 at JPMorgan

BillionToOne price target lowered to $130 from $140 at BTIG

2026-05-07T13:20:23.000Z - 6 days ago

BillionToOne price target lowered to $130 from $140 at BTIG

BillionToOne sees FY26 revenue $450M-$465M, consensus $437.6M

2026-05-07T00:59:44.000Z - 6 days ago

BillionToOne sees FY26 revenue $450M-$465M, consensus $437.6M

BillionToOne reports Q1 EPS 34c, consensus 4c

2026-05-07T00:59:19.000Z - 6 days ago

BillionToOne reports Q1 EPS 34c, consensus 4c

BillionToOne Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 days ago

BillionToOne Earnings Call Transcript: Q1 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

May 6, 2026, 4:05 PM EDT - 6 days ago

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

May 1, 2026, 7:00 PM EDT - 11 days ago

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

Apr 2, 2026, 9:00 AM EDT - 5 weeks ago

BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

BillionToOne price target lowered to $100 from $120 at Guggenheim

2026-03-30T11:55:33.000Z - 6 weeks ago

BillionToOne price target lowered to $100 from $120 at Guggenheim

BillionToOne price target lowered to $140 from $160 at BTIG

2026-03-05T12:50:24.000Z - 2 months ago

BillionToOne price target lowered to $140 from $160 at BTIG

BillionToOne price target lowered to $140 from $160 at BTIG

2026-03-05T12:28:04.000Z - 2 months ago

BillionToOne price target lowered to $140 from $160 at BTIG

BillionToOne price target lowered to $90 from $110 at Wells Fargo

2026-03-05T11:20:34.000Z - 2 months ago

BillionToOne price target lowered to $90 from $110 at Wells Fargo

BillionToOne reports Q4 EPS 11c, consensus 17c

2026-03-04T21:42:49.000Z - 2 months ago

BillionToOne reports Q4 EPS 11c, consensus 17c

BillionToOne raises FY26 revenue view to $430M-$445M from $415M-$430M

2026-03-04T21:40:40.000Z - 2 months ago

BillionToOne raises FY26 revenue view to $430M-$445M from $415M-$430M

BillionToOne Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 2 months ago

BillionToOne Earnings Call Transcript: Q4 2025

BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

Mar 4, 2026, 4:05 PM EST - 2 months ago

BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

Five new option listings and three option delistings on February 19th

2026-02-19T13:30:38.000Z - 2 months ago

Five new option listings and three option delistings on February 19th

VELO

BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 17, 2026, 8:05 AM EST - 3 months ago

BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®

Feb 10, 2026, 9:00 AM EST - 3 months ago

BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®

BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care

Feb 9, 2026, 12:29 PM EST - 3 months ago

BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care

BillionToOne collaborating with Epic for prenatal and oncology testing

2026-01-15T14:06:28.000Z - 4 months ago

BillionToOne collaborating with Epic for prenatal and oncology testing

BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare

Jan 15, 2026, 8:58 AM EST - 4 months ago

BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare

BillionToOne Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 4 months ago

BillionToOne Transcript: 44th Annual J.P. Morgan Healthcare Conference

BillionToOne sees FY26 revenue $415M-$430M, consensus $393.61M

2026-01-12T13:15:47.000Z - 4 months ago

BillionToOne sees FY26 revenue $415M-$430M, consensus $393.61M

BillionToOne Provides Guidance for 2026

Jan 12, 2026, 8:05 AM EST - 4 months ago

BillionToOne Provides Guidance for 2026

BillionToOne management to meet with BTIG

2026-01-07T17:30:14.000Z - 4 months ago

BillionToOne management to meet with BTIG

BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East

Jan 6, 2026, 9:00 AM EST - 4 months ago

BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East

BillionToOne initiated with a Buy at Guggenheim

2026-01-06T11:52:55.000Z - 4 months ago

BillionToOne initiated with a Buy at Guggenheim

BillionToOne falls -5.5%

2025-12-24T17:05:50.000Z - 4 months ago

BillionToOne falls -5.5%

BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 8:05 AM EST - 5 months ago

BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BillionToOne price target lowered to $145 from $150 at JPMorgan

2025-12-10T12:10:27.000Z - 5 months ago

BillionToOne price target lowered to $145 from $150 at JPMorgan

BillionToOne Earnings Call Transcript: Q3 2025

Dec 9, 2025, 4:30 PM EST - 5 months ago

BillionToOne Earnings Call Transcript: Q3 2025

BillionToOne reports Q3 EPS 10c, consensus 16c

2025-12-09T21:16:24.000Z - 5 months ago

BillionToOne reports Q3 EPS 10c, consensus 16c

BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

Dec 9, 2025, 4:07 PM EST - 5 months ago

BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

BillionToOne Reports Third Quarter 2025 Results

Dec 9, 2025, 4:05 PM EST - 5 months ago

BillionToOne Reports Third Quarter 2025 Results

BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025

Dec 2, 2025, 8:05 AM EST - 5 months ago

BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025

BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests

Dec 1, 2025, 6:49 AM EST - 5 months ago

BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests

Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering

Nov 6, 2025, 5:02 PM EST - 6 months ago

Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering

BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut

Nov 6, 2025, 12:44 PM EST - 6 months ago

BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut

Molecular diagnostics firm BillionToOne raises $273 million in US IPO

Nov 5, 2025, 10:36 PM EST - 6 months ago

Molecular diagnostics firm BillionToOne raises $273 million in US IPO

BillionToOne Announces Pricing of Upsized Initial Public Offering

Nov 5, 2025, 9:53 PM EST - 6 months ago

BillionToOne Announces Pricing of Upsized Initial Public Offering

BillionToOne Announces Launch of Initial Public Offering Roadshow

Oct 29, 2025, 6:00 AM EDT - 7 months ago

BillionToOne Announces Launch of Initial Public Offering Roadshow

BillionToOne targets over $2 billion valuation in US IPO

Oct 17, 2025, 6:09 PM EDT - 7 months ago

BillionToOne targets over $2 billion valuation in US IPO

Molecular diagnostics firm BillionToOne files for US IPO

Oct 7, 2025, 6:17 PM EDT - 7 months ago

Molecular diagnostics firm BillionToOne files for US IPO

BillionToOne IPO Registration Document (S-1)

Oct 7, 2025, 5:30 PM EDT - 7 months ago

BillionToOne IPO Registration Document (S-1)

Amb8675309
Amb8675309 May. 12 at 5:40 PM
$BLLN another prediction: once they settle out of court with ILMN, ILMN will want a licensing percentage of all the tests they’ve already done for whatever period it is they’re being sued for. So you’re most likely going to see an announcement of a one time payment to ILMN for those tests, PLUS they now they have to pay a percentage licensing fee going forward, on every test. This is in today’s environment where payors are paying less in general, reimbursement wise, on tests. So be careful of “spin” during earnings calls where they brag about testing volume- reality is if amount reimbursed per test is falling, plus now ILMN gets a percentage on each test… not a business to be in anymore…
1 · Reply
Amb8675309
Amb8675309 May. 12 at 5:31 PM
$BLLN they’ve been selling their test for years- IP owned by Illumina- they’ve got a deep hold on patents- probable end result- a licensing deal which will take a bite out of already decreasing margins due to payors decreasing reimbursement amounts. This will settle out of court. Look up all the companies that Illumina has already sued. CEO is hard headed to think this wasn’t coming once he went public and started to steal market share in the NIPT space…
0 · Reply
Amb8675309
Amb8675309 May. 12 at 5:18 PM
$BLLN look in my timeline for BLLN- I called it re lawsuits- thought NTRA would be the one- looks like Illumina- infringement on IP
1 · Reply
Pavie99
Pavie99 May. 12 at 4:14 PM
$BLLN cmon down to loading levels :) Shake n bake!!!! 🏎
0 · Reply
PhishTourFunds
PhishTourFunds May. 11 at 11:55 PM
$BLLN
0 · Reply
Shlobby
Shlobby May. 11 at 10:56 PM
$BLLN they will find this 50 to 100% higher
1 · Reply
SmashDipRoll
SmashDipRoll May. 11 at 7:48 PM
$BLLN
0 · Reply
Shlobby
Shlobby May. 11 at 7:47 PM
Theres a new $BILI in town @Doozio cc $BLLN
0 · Reply
Bounty_Hunter1
Bounty_Hunter1 May. 11 at 6:52 PM
$BLLN
0 · Reply
Reanimated666
Reanimated666 May. 11 at 3:54 PM
$BLLN couldn’t make sense of the numbers yet this thing keeps going up I guess it’s good 👍
1 · Reply
Grouphome
Grouphome May. 9 at 1:20 PM
$BLLN
0 · Reply
Bazzzigar
Bazzzigar May. 8 at 2:17 PM
$BLLN
0 · Reply
PremonitionX
PremonitionX May. 8 at 6:47 AM
$BLLN
0 · Reply
Bounty_Hunter1
Bounty_Hunter1 May. 7 at 10:46 PM
$BLLN Interesting stock 🤔
0 · Reply
prodigy81
prodigy81 May. 7 at 8:27 PM
$CAI $BLLN $GRAL Do they have common in cancer diagonisic area right?
0 · Reply
Agile_Mango_Penguin
Agile_Mango_Penguin May. 7 at 6:21 PM
$BLLN hovering around IPO VWAP here with YUGE weekly bar 👀
0 · Reply
Bazzzigar
Bazzzigar May. 7 at 4:39 PM
$BLLN pure pumping
0 · Reply
Walknastie
Walknastie May. 7 at 2:28 AM
$BLLN premeditated fraud
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 9:28 PM
$BLLN Q1 '26 Earnings Results & Recap BillionToOne is required to maintain trailing six-month net revenue gradually increasing up to $120M by December 31, 2026, and a trailing six-month gross margin of not less than 30%.
0 · Reply
Reanimated666
Reanimated666 May. 4 at 9:57 AM
$BLLN PE is sky here. waiting for earnings to make any move
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 11:12 PM
$BLLN Share Price: $78.34 Contract Selected: Dec 18, 2026 $80 Calls Buy Zone: $12.83 – $15.86 Target Zone: $23.98 – $29.31 Potential Upside: 76% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
GordoHLYK13
GordoHLYK13 Apr. 28 at 11:08 AM
$BLLN $GH $NEO $NEO calling NeoGenomics “old tech” is lazy DD. They already evolved from legacy heme into one of the broadest precision oncology platforms in the game. Community oncology access matters more than hype, and $NEO already has the doctor relationships others still chasing. MRD in colon, lung, breast is still early innings. While others flex TAM slides, $NEO has the footprint to monetize real patient volume NOW. RaDaR / ctDNA = sticky repeat testing revenue once clinicians adopt it. That’s how long-term value gets built. Get ready buddy earnings today after market
1 · Reply